Phase I trial of combined chemotherapy of bevacizumab, panitumumab and irinotecan as 3rd-line chemotherapy in chmotherapy-refractory metastatic colorectal cancer.
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: Combined chemotherapy of bevacizumab, panitumumab, irinotecan. Primary outcome(s): Proportion of dose limiting toxicity (DLT). Study Design: Single arm Non-randomized
创建时间：
2012-11-15
